+39 02 610346.1 - info@newron.com

Pipeline

Pipeline

Newron has built a well-balanced pipeline of innovative CNS and pain treatments, including safinamide for Parkinson’s disease, licensed to Zambon Group and Meiji Seika Pharma, for which CHMP has recommended approval in the EU and filing submitted to FDA and Swissmedic; sarizotan for Rett syndrome, ralfinamide for specific pain indications, and NW-3509 as, potentially, the first add-on therapy for the treatment of schizophrenia.